Paper14565784
Dutasteride.
Evans HC and 1 other. Drugs Aging, 2003. Cited by 41 papers, by iCite.
Cite this record
ConductScience Library. Dutasteride. Papers, record 14565784. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/14565784
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| 5-alpha Reductase Inhibitors | Major topic |
| Azasteroids | Major topic |
| Prostatic Hyperplasia | Major topic |
| Drug Therapy, Combination | |
| Dutasteride | |
| Humans | |
| Male | |
| Prostate-Specific Antigen | |
| Randomized Controlled Trials as Topic |
Source PubMed
References13
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 7577933 | Mechanism of time-dependent inhibition of 5 alpha-reductases by delta 1-4-azasteroids: toward perfection of rates of time-dependent inhibition by using ligand-binding energies. | Biochemistry | 1995 | https://conductscience.org/library/papers/7577933 | PubMed |
| 2 | 12814679 | Safety and tolerability of the dual 5alpha-reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia. | Eur Urol | 2003 | https://conductscience.org/library/papers/12814679 | PubMed |
| 3 | 9143856 | Benign prostatic hyperplasia. Practical treatment guidelines. | Drugs Aging | 1997 | https://conductscience.org/library/papers/9143856 | PubMed |
| 4 | 9061268 | Treatment of benign prostatic hyperplasia. A pharmacoeconomic perspective. | Drugs Aging | 1997 | https://conductscience.org/library/papers/9061268 | PubMed |
| 5 | 10235693 | Finasteride: an update of its use in the management of symptomatic benign prostatic hyperplasia. | Drugs | 1999 | https://conductscience.org/library/papers/10235693 | PubMed |
| 6 | 9871428 | A model for the turnover of dihydrotestosterone in the presence of the irreversible 5 alpha-reductase inhibitors GI198745 and finasteride. | Clin Pharmacol Ther | 1998 | https://conductscience.org/library/papers/9871428 | PubMed |
| 7 | 9760689 | Discovery and development of GG745, a potent inhibitor of both isozymes of 5 alpha-reductase. | Pharm Biotechnol | 1998 | https://conductscience.org/library/papers/9760689 | PubMed |
| 8 | 12887480 | Improvements in benign prostatic hyperplasia-specific quality of life with dutasteride, the novel dual 5alpha-reductase inhibitor. | BJU Int | 2003 | https://conductscience.org/library/papers/12887480 | PubMed |
| 9 | 9316864 | Unique preclinical characteristics of GG745, a potent dual inhibitor of 5AR. | J Pharmacol Exp Ther | 1997 | https://conductscience.org/library/papers/9316864 | PubMed |
| 10 | 10073740 | The pharmacokinetic modelling of GI198745 (dutasteride), a compound with parallel linear and nonlinear elimination. | Br J Clin Pharmacol | 1999 | https://conductscience.org/library/papers/10073740 | PubMed |
| 11 | 12350480 | Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. | Urology | 2002 | https://conductscience.org/library/papers/12350480 | PubMed |
| 12 | 9951948 | Alpha-adrenoceptor antagonists in the treatment of benign prostatic hyperplasia. | Drugs | 1999 | https://conductscience.org/library/papers/9951948 | PubMed |
| 13 | 15126539 | Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor. | J Clin Endocrinol Metab | 2004 | https://conductscience.org/library/papers/15126539 | PubMed |
Cited by16
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 41 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41405174 | Impact of Administration Time Errors on Clearance Estimation in Pharmacokinetic Analyses. | Clin Transl Sci | 2025 | https://conductscience.org/library/papers/41405174 | PubMed |
| 40114308 | Long-term use of dutasteride to treat androgenic alopecia in young men may lead to persistent abnormalities in semen parameters. | Clin Exp Reprod Med | 2025 | https://conductscience.org/library/papers/40114308 | PubMed |
| 39091900 | Enhancing hair regeneration: Recent progress in tailoring nanostructured lipid carriers through surface modification strategies. | ADMET DMPK | 2024 | https://conductscience.org/library/papers/39091900 | PubMed |
| 38243983 | Current Understanding of Androgen Signaling in Prostatitis and its Treatment: A Review. | Curr Med Chem | 2024 | https://conductscience.org/library/papers/38243983 | PubMed |
| 32742388 | Efficacy and safety of dutasteride compared with finasteride in treating males with benign prostatic hyperplasia: A meta-analysis of randomized controlled trials. | Exp Ther Med | 2020 | https://conductscience.org/library/papers/32742388 | PubMed |
| 30871552 | Meta-analysis of the efficacy and safety of combination of tamsulosin plus dutasteride compared with tamsulosin monotherapy in treating benign prostatic hyperplasia. | BMC Urol | 2019 | https://conductscience.org/library/papers/30871552 | PubMed |
| 30367429 | Neuropsychological Assessment in Elderly Men with Benign Prostatic Hyperplasia Treated with Dutasteride. | Clin Drug Investig | 2019 | https://conductscience.org/library/papers/30367429 | PubMed |
| 29379733 | The use of 5-alpha reductase inhibitors in the treatment of benign prostatic hyperplasia. | Asian J Urol | 2018 | https://conductscience.org/library/papers/29379733 | PubMed |
| 29153901 | Use of 5-alpha-reductase inhibitors as alternatives to luteinizing-hormone releasing hormone (LHRH) analogs or anti-androgens for prostate downsizing before brachytherapy. | Pract Radiat Oncol | 2018 | https://conductscience.org/library/papers/29153901 | PubMed |
| 27364517 | Impact of Formulation on the Pharmacokinetic Profile of Dutasteride. | Clin Drug Investig | 2016 | https://conductscience.org/library/papers/27364517 | PubMed |
| 25984604 | Preparation and in vivo evaluation of a dutasteride-loaded solid-supersaturatable self-microemulsifying drug delivery system. | Int J Mol Sci | 2015 | https://conductscience.org/library/papers/25984604 | PubMed |
| 25753982 | Patients with Persistently Elevated PSA and Negative Results of TRUS-Biopsy: Does 6-Month Treatment with Dutasteride can Indicate Candidates for Re-Biopsy. What is the Best of Saturation Schemes: Transrectal or Transperineal Approach? | Pathol Oncol Res | 2015 | https://conductscience.org/library/papers/25753982 | PubMed |
| 24872577 | Relative adrenal insufficiency in mice deficient in 5α-reductase 1. | J Endocrinol | 2014 | https://conductscience.org/library/papers/24872577 | PubMed |
| 23737668 | Influence of hydrophilic additives on the supersaturation and bioavailability of dutasteride-loaded hydroxypropyl-β-cyclodextrin nanostructures. | Int J Nanomedicine | 2013 | https://conductscience.org/library/papers/23737668 | PubMed |
| 21629218 | Targeting 5α-reductase for prostate cancer prevention and treatment. | Nat Rev Urol | 2011 | https://conductscience.org/library/papers/21629218 | PubMed |
| 19030020 | 5alpha-Reductase inhibitor treatment of prostatic diseases: background and practical implications. | Prostate Cancer Prostatic Dis | 2009 | https://conductscience.org/library/papers/19030020 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/14565784
GET https://conductscience.org/api/papers/v1/14565784/authors